An interaction has been reported between high-dose methotrexate and a macrolide-like antibiotic pristinamycin. 4 In that interaction, methotrexate elimination was dramatiTacrolimus (FK506) is a macrolide lactone effective in the control of graft-versus-host disease (GVHD). An cally altered with high serum concentrations of methotrexate persisting above the micromolar level for several days. interaction between high-dose methotrexate and a macrolide antibiotic (pristinamycin) leading to prolonged This prolonged methotrexate exposure led to severe toxicity including oral mucositis, anusitis, balanitis, and hematomethotrexate exposure has been described. Because a randomized prospective trial comparing tacrolimus logic toxicity despite hemodiafiltration. In an earlier report in six patients we did not detect any clinically meaningful with cyclosporine (both in combination with methotrexate) following allogeneic BMT showed the tacdifference in methotrexate levels measured once at 24 h after each dose in patients given tacrolimus compared to rolimus plus methotrexate regimen to be more effective in prevention of GVHD, we assessed methotrexate pharcyclosporine. 5 In this study, we formally assessed methotrexate pharmacokinetics at multiple time-points in a larger macokinetics in a subgroup of the participants of this trial to evaluate the possibility that an interaction of cohort of patients participating in a randomized clinical trial comparing tacrolimus with cyclosporine, both given in FK506 and methotrexate was the explanation for the clinical findings. Mean and median methotrexate levels combination with methotrexate, following allogeneic marrow transplantation, to determine if the greater efficacy seen at various time-points after the day 1 and 6 methotrexate doses were comparable in the tacrolimus and cyclowith FK506 can be attributed to an interaction with methotrexate which might potentiate the methotrexate exposure. sporine cohorts and were elevated in only three of 70 study patients. Area under the curve (AUC) concentrations were also similar after the day 1 and 6 methotrexate doses. Thus, no significant interaction between Methods tacrolimus and methotrexate is apparent and the differences in efficacy between tacrolimus and cyclosporine Patients aged 12 years or older undergoing allogeneic BMT using HLA-identical sibling donors for a malignancy were are unlikely to be attributable to pharmacologic interactions with methotrexate.
In that interaction, methotrexate elimination was dramatiTacrolimus (FK506) is a macrolide lactone effective in the control of graft-versus-host disease (GVHD). An cally altered with high serum concentrations of methotrexate persisting above the micromolar level for several days. interaction between high-dose methotrexate and a macrolide antibiotic (pristinamycin) leading to prolonged This prolonged methotrexate exposure led to severe toxicity including oral mucositis, anusitis, balanitis, and hematomethotrexate exposure has been described. Because a randomized prospective trial comparing tacrolimus logic toxicity despite hemodiafiltration. In an earlier report in six patients we did not detect any clinically meaningful with cyclosporine (both in combination with methotrexate) following allogeneic BMT showed the tacdifference in methotrexate levels measured once at 24 h after each dose in patients given tacrolimus compared to rolimus plus methotrexate regimen to be more effective in prevention of GVHD, we assessed methotrexate pharcyclosporine. 5 In this study, we formally assessed methotrexate pharmacokinetics at multiple time-points in a larger macokinetics in a subgroup of the participants of this trial to evaluate the possibility that an interaction of cohort of patients participating in a randomized clinical trial comparing tacrolimus with cyclosporine, both given in FK506 and methotrexate was the explanation for the clinical findings. Mean and median methotrexate levels combination with methotrexate, following allogeneic marrow transplantation, to determine if the greater efficacy seen at various time-points after the day 1 and 6 methotrexate doses were comparable in the tacrolimus and cyclowith FK506 can be attributed to an interaction with methotrexate which might potentiate the methotrexate exposure. sporine cohorts and were elevated in only three of 70 study patients. Area under the curve (AUC) concentrations were also similar after the day 1 and 6 methotrexate doses. Thus, no significant interaction between Methods tacrolimus and methotrexate is apparent and the differences in efficacy between tacrolimus and cyclosporine Patients aged 12 years or older undergoing allogeneic BMT using HLA-identical sibling donors for a malignancy were are unlikely to be attributable to pharmacologic interactions with methotrexate.
enrolled in a randomized trial comparing tacrolimus plus methotrexate with CsA plus methotrexate as GVH prophyKeywords: tacrolimus; methotrexate; graft-versus-host disease; FK506 laxis. During this multicenter clinical trial, patients from six centers were enrolled in a pharmacokinetic substudy in which methotrexate pharmacokinetics were evaluated. Patients were excluded from the study if they had a serum Tacrolimus (FK506) is a macrolide lactone produced by creatinine у3.0 mg/dl or known hypersensitivity to chromStreptomyces tsukubaensis which has been noted to be ophore or related products. Patients were also excluded if effective either alone or in combination with short-course they were seropositive to the human immunodeficiency methotrexate or methylprednisolone as prophylaxis for virus, recipients of a T lymphocyte-depleted marrow graft, GVHD.
1,2 In a recent prospective randomized trial comparor pregnant. The protocol and consent forms were approved ing cyclosporine (CsA) plus methotrexate with FK506 plus by each center's institutional review board and written conmethotrexate as prophylaxis against GVHD, a lower rate sent was obtained by all the patients. of acute GVHD was observed in the group receiving FK506
Patients received the pretransplant cytotoxic conditioning plus methotrexate. diagnoses were acute leukemia in 25 and 38%, chronic leuof methotrexate at various time-points after the day 1 and day 6 methotrexate doses are provided. There were no sigkemia in 39 and 35%, lymphoma in 14 and 18%, and other in 22 and 5% in the FK506 and CsA groups, respectively. nificant differences between the CsA and tacrolimus cohorts in these values at any of the time-points sampled. In only four evaluations (in three patients), were methotrexate Graft-versus-host disease prophylaxis concentrations at 24 h greater than or equal to 0.05 m/l. Of Patients received tacrolimus at a dose of 0.03 mg/kg based these four instances, two were in the same patient receiving on the lesser of actual or lean body weight, given intratacrolimus; elevated 24-h concentrations were noted both venously as a continuous infusion beginning 1 day before on day 1 and day 6. In this patient, the renal function was the marrow infusion (day −1). Cyclosporine was given at normal on day 1, but on day 6 the creatinine had increased a dose of 3.0 mg/kg/day intravenously as a continuous by 50% (but was still within normal limits) and the estiinfusion beginning 1 day before marrow infusion. Patients mated creatinine clearance had decreased from 152 ml/min continued intravenous medication during this pharmacokito 98 ml/min. In a second patient (receiving CsA) with an netic study. Methotrexate was given at a dose of 15 mg/m 2 elevated methotrexate level at 24 h, the patient's creatinine on day 1 followed by 10 mg/m 2 on days 3, 6, and 11 postwas elevated prior to the methotrexate dose. The patient transplant. Tacrolimus whole blood levels were measured did not receive a day 6 methotrexate dose. The third patient three times weekly and doses were adjusted to maintain (receiving tacrolimus) with an elevated methotrexate conserum levels between 15 and 30 ng/ml as measured by centration on day 6 had normal renal and hepatic function; whole blood IM x (Abbott, Chicago, IL, USA). Cyclosporthis patient had not been studied on day 1. ine doses were similarly monitored and whole blood levels
The mean and median serum creatinine concentrations were maintained between 100 and 400 ng/ml as measured and estimated creatinine clearances were not significantly by whole blood HPLC or monoclonal immunoassay. Both different between patients receiving FK506 and those tacrolimus and CsA were dose reduced if moderate to sevreceiving CsA on Days 1 and 6 (data not shown). The mean ere adverse effects occurred attributable to either drug. and median AUC serum methotrexate concentrations in patients receiving tacrolimus and CsA on days 1 and 6 are Pharmacokinetic monitoring presented in Table 2 . The methotrexate AUCs were compaSerum methotrexate concentrations were assayed before rable in the two groups. and at 8, 16, 24, and 36 h after the day 1 and day 6 methoTo examine whether there might be a difference in trexate doses. All serum samples were analyzed at a central methotrexate renal clearance between patients with nonlaboratory using the fluorescence polarization immunoassay advanced disease vs those with advanced disease (since (TxD; Abbott). 6 transplant-related mortality and morbidity rates are different in these cohorts), mean and median values of methoAnalysis trexate AUC values were compared in those subgroups. There were no significant differences noted (data not Methotrexate area under the curve (AUC) serum concenshown). trations were calculated by the trapezoidal rule. Means were compared using the Student's t-test.
Discussion Results
Eighty patients consented to participate, 40 receiving cycloDespite concerns about a potential interaction between high-dose methotrexate and another macrolide-like molesporine plus methotrexate and 40 receiving tacrolimus plus methotrexate. Sixteen and 26 patients, respectively, were cule, pristinamycin, that could result in impaired clearance of methotrexate and potentiation of methotrexate toxicity, not included in the day 1 and day 6 analyses because they either did not receive a full dose of methotrexate or did not these data suggest that there is no significant pharmacologic interaction between low-dose methotrexate and tacrolimus have all the samples collected.
In Table 1 , the mean and median serum concentrations in the dose schedule administered in this study. In only 
